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A continuous intravenous infusion was used to assess the tissue penetration of cefazolin (14 subjects) and
cefuroxime (15 subjects) in orthopedic surgery patients. Subjects were randomly assed to receive a
continuous intravenous infusion of cefazolin (mean, 178.6 mg/h) or cefuroxime (mean, 330.0 mg/h) at a rate
estimated to achieve a target steady-state total concentration of 50 glmnl in serum. The infus was initiated
12 to 14 h before surgery, and blood and muscle tissue samples were colected intraoperatively at the times of
incision and wound dosure. Although there was a gnificant difference between the free concentrations of
cefazolin (at incision, 9.3 gLg/ml; at closure, 9.2 pg/ml) and cefuroxime in serum (at incIsion, 26.9 pg/ml; at
closure, 31.8 pg/mi), there was no difference in the total concentrations in muscle at either surgical incision
(cefazolin, 6.1 pg/g; cefuroxine, 5.6 pg/g) or wound closure (cefazolin, 7.7 pg/g; cefuroxime, 7.4 pg/g). There
was a significant correlation between the pooled free serum and total muscle concentrations for cefazoin (P =
0.001); however, there was no correlation between these variables with the pooled cefuroxime data (P = 0.403).
These findings indicate that'the free drug concentration in serum alone is not consistently predictive of the total
concentration of cephalosporin in muscle.
Although the relationships between the total and free drug
concentrations in serum and their concurrent concentrations
in tissues have been the object of much study, these rela-
tionships remain uncertain, and their clinical significance is
controversial. Studies of antimicrobial tissue penetration
have typically utilized a single dose of antimicrobial agent
administered via a short intravenous (i.v.) infusion.
The goal of the present study was to assess under steady-
state conditions the effect of serum protein binding on the
tissue penetration of two cephalosporins, cefazolin and
cefuroxime, administered by continuous i.v. infusion. The
specific objectives of this study were to determine the
concentrations of free and total drug in serum and total drug
in muscle by using a continuous-infusion model in patients
undergoing orthopedic surgery and to determine the relation-
ships between these concentrations. Cefazolin and cefurox-
ime were selected as study drugs based on considerations for
patient safety and differences in serum protein binding.
Cefazolin is considered a drug of choice for'surgical prophy-
laxis in total hip replacement and internal fixation of frac-
tures, and cefuroxime has also been effective for these
purposes (1, 6, 15). These drugs differ significantly in their
degree of serum protein binding (cefazolin, 74 to 86%;
cefuroxime, 33 to 50%), allowing for comparison of study
parameters.
MATERIALS AND METHODS
Subjects. This study was approved by the institutional
review board at the Medical College of Georgia and the
Veterans Administration Medical Center, and all subjects
provided written informed consent before being enrolled in
the study. Subjects were hospitalized patients on the ortho-
* Corresponding author.
t Present address: Philadelphia College of Pharmacy and Science,
Philadelphia, PA 19104.
pedic surgery service at the two institutions who were
undergoing primary total hip replacement or open repair of a
hip or femur fracture. Subjects were required to be at least
18 years of age, have a creatinine clearance greater than 50
ml/min, and be within 15% of their ideal body weight.
Exclusion criteria included history of a type I hypersensitiv-
ity reaction to penicillin or any reaction to a cephalosporin
antibiotic, evidence of active cardiac or hepatic disease,
history of severe hematologic disease or host defense im-
pairment (absolute neutrophil count less than 2,000/mm3),
pregnancy or lactation, and evidence or suspicion of infec-
tion in the operative site at the time of surgery. In addition,
subjects could not have received any antimicrobial agent
within 72 h before surgery or received additional antimicro-
bial agents during the operation other than topical antimicro-
bial irrigation.
Study design, dosage calculations, and drug administration.
Subjects were randomly assigned to receive a continuous
i.v. infusion of cefazolin (Ancef; Smith Kline & French
Laboratories, Philadelphia, Pa.) or cefuroxime (Zinacef;
Glaxo Inc., Research Triangle Park, N.C.). The i.v. infusion
rate was determined by using the model-independent rela-
tionship ko = CL x Css, where ko is the i.v. infusion rate
(milligrams per hour), CL is the total clearance of the study
drug (liters per hour), and C., is the desired total concentra-
tion in serum at steady state (milligrams per liter). The target
C,. for all subjects was 50 pg/ml. The CL for each subject
was estimated based on creatinine clearance (CLCR) as
predicted by the method of Cockcroft and Gault (4). Cefazo-
lin CL, as shown below, was estimated from data collected
in two previously published studies of 30 patients that
received cefazolin preoperatively (7, 11). The range of
creatinine clearance values in those patients was 50 to 120
ml/min. Cefazolin CL was calculated as 0.598(CLcR) +
0.736, where CLs are in liters per hour.
Cefuroxime CL, in liters per hour, was estimated as Vr, x
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kel. The estimated steady-state volume (liters) of distribution
(V,,) of cefuroxime was obtained from published information
(0.19 liter/kg of body weight) (3). The elimination rate
constant (kei; h-') was estimated by using the subject's
calculated CLCR standardized to body surface area. A CLCR
of less than 65 ml/min per 1.73 m2 was estimated to be
associated with a kel of 0.277 h-1; likewise, creatinine
clearances of 65 to 79, 80 to 104, 105 to 115, and greater than
115 ml/min per 1.73 m2 were estimated to be associated with
elimination rate constants of 0.347, 0.462, 0.554, and 0.6 h',
respectively (3).
The continuous i.v. infusion of cefazolin or cefuroxime
was initiated 12 or 14 h, respectively, before the start of the
operation to allow adequate time for the attainment of
steady-state conditions before biologic sampling in the oper-
ating room. The study drug was infused via a syringe pump
(Auto Syringe model AS2F; Travenol Laboratories, Hook-
sett, N.H.). Once the infusion was initiated, the rate was
held constant until the infusion was discontinued in the
postoperative recovery room.
Biologic sampling and drug assays. Venous blood samples
of 10 ml were obtained at the time of the initial surgical
incision and at wound closure. The serum was harvested and
stored in glass vials at -80°C until assayed. A 1-g sample of
viable muscle was obtained from the surgical site concurrent
with the blood samples. Muscle samples were blotted dry
with surgical gauze and stored at -80°C.
The concentrations of free and total drug in serum and
total drug in homogenized muscle were determined by
high-performance liquid chromatography (HPLC). The
HPLC system included the following (all from Millipore
Waters Associates, Milford, Mass.): pump (model 510),
autosampler (WISP model 710B), and spectrophotometer set
at a wavelength of 254 nm (Lambda-Max model 481). Peak
heights were recorded on a thermal reporter-integrator
(model 3390A; Hewlett Packard Co., Avondale, Pa.). The
stationary phase for all assays consisted of a C18 precolumn
attached to a C18 25-cm reversed-phase column. The mobile
phase for all cefazolin assays was 11% (vol/vol) acetonitrile
in 0.1 M sodium acetate buffer (pH adjusted to 3.85) at a flow
rate of 2.0 ml/min. The mobile phase for all cefuroxime
assays was 10% (vol/vol) acetonitrile in 0.1 M sodium
acetate buffer (pH adjusted to 3.85), also at a flow rate of 2.0
ml/min.
For determination of total cefazolin in serum, 500,ul of
acetonitrile and 25 Rl of cefoxitin internal standard (0.1
mg/ml) were added to 100 ,ul of serum test samples and
vortexed. This mixture was centrifuged (model Centra 4;
International Equipment Co., Needham Heights, Mass.) at
3,000 rpm for 10 min, and 10 RI of the clear eluent was
injected onto the HPLC column. The concentration of free
cefazolin in serum was obtained by ultrafiltration with an
Amicon MPS filter system with a YMT membrane (Amicon
Corp., Danvers, Mass.). Serum (1 ml) was centrifuged at
3,000 rpm for 6 min to yield 150,u of ultrafiltrate. Then 25,u
of 8-chlorotheophylline internal standard (100,ug/ml) was
added to 100 RI of protein-free filtrate and vortexed, and 10
,lI was injected onto the HPLC column. To determine the
total concentration of cefazolin in muscle, 2 ml of Sorensen
phosphate buffer (pH 7.4) was added to 500 mg of frozen
muscle. The frozen muscle sample was placed in an ice bath
and homogenized for less than 1 min with a tissue homoge-
nizer (Tissumizer TRST; Tekmar Co., Cincinnati, Ohio).
The homogenate was vortexed and then centrifuged for 10
min at 3,000 rpm. Solid-phase extraction of cefazolin from
the homogenate was done on a C18 column (Prep-sep; Fisher
Scientific Co., Pittsburgh, Pa.) by taking 500 RI of eluent
from the centrifuged homogenate and washing it with 1 ml of
purified water on the column, followed by extraction of the
drug from the column with 1 ml of methanol. Then 20 RI of
8-chlorotheophylline internal standard (50 ,ug/ml) was added
to 500 ,ul of the resulting eluent and vortexed, and 30 RI was
injected onto the HPLC column.
The concentrations of total and free cefuroxime in serum
and the concentration of total cefuroxime in muscle were
determined as described above for cefazolin. 8-Chlorotheo-
phylline was the internal standard for all cefuroxime assays.
The standard curve ranges for the cefazolin assays were 10
to 100 ,ug/ml, 2 to 30 ,ug/ml, and 2 to 15 ,ug/g for the total and
free drug concentrations in serum and total drug concentra-
tion in muscle, respectively. The ranges for the standard
curves of the cefuroxime assays were 10 to 100 ,ug/ml, 5 to 50
,g/ml, and 2 to 50 ,ug/g for the total and free drug concen-
trations in serum and total drug concentration in muscle,
respectively. The standard curve for each of the study drugs
in muscle was prepared with porcine muscle. Because of the
limited amount of clinical material (0.5 to 1 g), drug stability
tests were not undertaken. The sensitivities were 1 jig/ml
and 1 ,ug/g for all serum and muscle assays, respectively.
The r2 for the standard curves ranged from 0.990 to 0.999.
The intraday coefficients of variation were 5.9 and 8.9% for
cefazolin and cefuroxime in muscle at 2 ,ug/g, respectively.
For serum (total and free), they were usually less than 5%.
Data analysis. Mean concentration data obtained at surgi-
cal incision and wound closure were compared within sub-
jects by using paired t tests. Comparisons between drugs
were performed with independent t tests. The associations
between concentrations were tested with the Pearson corre-
lation coefficient. Two-tailed tests were used for all compar-
isons, and the a priori level of statistical significance was set
at P< 0.05.
RESULTS
Of the 34 patients enrolled in the study, 5 were withdrawn
for the following reasons: inability to start an i.v. to admin-
ister the study drug (2 patients), malfunction of the i.v.
infusion pump (1 patient), inability to maintain the infusion
(1 patient), and failure to begin the infusion at the proper
time (1 patient). Of the 29 evaluable subjects, 14 received
cefazolin and 15 received cefuroxime. Subjects in the two
study groups did not differ significantly (P > 0.05) with
regard to the following (means + standard deviations): age
(cefazolin, 48.1 + 12.5 years; cefuroxime, 45.9 + 17.6
years), calculated creatinine clearance (cefazolin, 76.6 ±
25.6 mlmin; cefuroxime, 88.5 + 26.4 mlmin) and serum
albumin (cefazolin, 4.8 + 0.5 g/dl; cefuroxime, 4.5 + 0.4
g/dl). The mean infusion rates of cefazolin and cefuroxime
were 178.6 ± 46.9 and 330.0 + 114.6 mg/h, respectively (P<
0.001). The mean duration of surgery for subjects receiving
cefazolin and cefuroxime was 94.2 ± 21.5 and 105.4 + 32.8
min, respectively (P > 0.05). Surgical procedures were
begun between 8:00 a.m. and 2:00 p.m. and used a variety of
anesthetic agents.
The mean concentration data obtained at surgical incision
and wound closure for both antibiotics are summarized in
Table 1. Comparisons within subjects of cefazolin concen-
trations obtained at incision and wound closure were not
significant (P > 0.05). However, there were significant
intrasubject differences in the cefuroxime total serum (P <
0.05), free serum (P< 0.01), and total muscle (P = 0.001)
concentrations at incision and wound closure.
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TABLE 1. Mean concentration data (mean ± standard deviation)
Antimicrobial Time of Concn (p,g/ml) in serum Concn in muscle Muscle/free Free serum/total
agent sampling Free Total (4g/g) serum ratio serum ratio
Cefazolin (n = 14) Incision 9.3 ± 3.3 52.8 ± 14.0a 6.1 ± 3.3 0.64 ± 0.24 0.17 ± 0.04a
Closure 9.2 ± 2.8 51.8 ± 12.8 7.7 ± 4.9 0.82 ± 0.41 0.18 ± 0.05
Cefuroxime (n = 15) Incision 26.9 ± 9.lb 36.2 ± 13.4b 5.6 ± 3.6 0.23 ± 0.20b 0.75 ± 0.04b
Closure 31.8 ± 11.8 40.9 ± 15.5 7.4 ± 2.5b 0.24 ± 0.08b 0.79 ± 0.12
an= 13.
b n = 14.
The concentrations of total cefazolin and cefuroxime in
muscle were not statistically different (surgical incision, P =
0.74; wound closure, P = 0.86) despite significant differences
between drugs in both total and free drug concentrations in
serum. For cefazolin, there were significant correlations
between total and free drug concentrations in serum at both
surgical incision and wound closure and between free drug
concentration in serum and total concentration in muscle at
surgical incision. At wound closure, the correlation between
free cefazolin concentration in serum and total concentration
in muscle also approached statistical significance (P =
0.059). For cefuroxime, the only significant correlations
were between total and free concentrations in serum at
surgical incision and wound closure (Table 2). When the
incision and closure concentration data for each drug were
pooled, there were significant correlations between total and
free concentrations in serum for both cefazolin and cefurox-
ime and between the concentration offree cefazolin in serum
and total concentration in muscle (Table 3).
DISCUSSION
Generally it is believed that only free, unbound antimicro-
bial agents are able to interact with microorganisms to exert
a pharmacologic effect (17). Most pathogenic bacteria reside
in tissue sites outside of the vascular system; therefore, the
tissue penetration of free drug is important for drug efficacy.
In the present study we utilized a continuous i.v. infusion
under steady-state conditions to control for the total concen-
TABLE 2. Correlations between concentration parameters
Concn Cefazolin (n = 14) Cefuroxime (n = 15)
parameters r p r P
Incision
Total serum and 0.742 0.004c 0.992 <0.001d
free serum
Total serum and 0.339 0.257C -0.112 0.702d
total muscle
Free serum and 0.811 <0.001 -0.132 0.654d
total muscle
Closure
Total serum and 0.547 0.043 0.955 <0.001
free serum
Total serum and -0.197 0.501 0.297 0.303d
total muscle
Free serum and 0.516 0.059 0.377 0.183d
total muscle
aPearson correlation coefficient.
bTwo-tailed P value.
Cn = 13.dn= 14.
tration of drug in serum and drug clearance. At steady state,
the concentrations of free drug in the vascular and extravas-
cular compartments are expected to be similar. Despite
significant differences in the concentrations of free cefazolin
and cefuroxime in serum, we found no significant difference
in the concentration of total drug in muscle. This was an
unexpected finding and suggests that the concentration of
free drug in serum alone is not a consistent predictor of the
total concentration in tissue. The total concentration of drug
in the tissue is dependent on the concentrations of both
bound and free drug in the extravascular space. Since
cefazolin protein binding in serum is significantly greater
than that of cefuroxime, it would be anticipated that cefazo-
lin protein binding in the extravascular space would also be
greater. A possible explanation for the observation that
cefazolin and cefuroxime had similar total concentrations in
muscle despite having significant differences in their free
concentrations in serum may relate to binding of cefazolin to
proteins in the extravascular space. Possibly there is less
free cefazolin than cefuroxime in the tissues, as would be
predicted; however, the higher protein binding of cefazolin
in tissue may have resulted in our observation that total
concentrations of the two drugs in muscle were equivalent.
Results of this study cannot be extrapolated to cefazolin and
cefuroxime concentrations in serum outside the range of the
study. Although in the present study we measured the
concentration of total drug in tissue, it would have been
desirable to also measure the concentration of free drug in
muscle. However, homogenization of the tissue destroys the
interrelationships of tissue components, resulting in a con-
glomerate containing muscle, interstitial fluid, cell cyto-
plasm, and possibly blood (2). Determination of the free drug
concentration in this conglomerate would not be a reliable
measure of free drug in the extracellular fluid. Therefore,
determination of free drug in tissue homogenates is generally
not performed.
TABLE 3. Correlations between pooled (incision plus closure)
concentration parameters
Concn Cefazolin (n = 28) Cefuroxime (n = 30)
parameters p r P
Total serum and 0.643 <0.001C 0.966 <0.001d
free serum
Total serum and 0.002 0.993c 0.109 0.579
total muscle
Free serum and 0.607 0.001 0.165 0.403e
total muscle
a Pearson correlation coefficient.
b Two-tailed P value.
Cn = 27.
d n = 29.
' n = 28.
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Although the mean total concentration of cefazolin in
serum closely approximated the target concentration of 50
jig/ml, the mean total concentration of cefuroxime in serum
fell considerably short of this goal. The reasons for not
achieving the target concentration are not apparent but may
relate to one of the components used to estimate cefuroxime
clearance.
The bacteria most frequently associated with deep wound
infections after orthopedic surgery are Staphylococcus au-
reus and Staphylococcus epidermidis (1). For cefuroxime,
the MICs for 90% of S. aureus and S. epidermidis isolates
are 1.4 and 0.98 ,ug/ml, respectively (10). Ninety-six percent
of S. aureus isolates and 94% of S. epidermidis isolates are
inhibited by cefazolin concentrations of 2.0 and 4.0 ,ug/ml,
respectively (12). The concentration of cefuroxime in muscle
exceeded the MIC for 90% of staphylococci in all subjects.
Of 14 subjects receiving cefazolin, 1 had drug concentrations
in muscle of less than 2 jig/g, and 3 had drug concentrations
of less than 4 ,ug/g (range, 1.3 to 3.9 jig/g). No postoperative
infections were noted in either study group. The optimal
antimicrobial concentration in tissue for preventing postop-
erative infection and its relationship to the MIC for poten-
tially infecting organisms are still unknown.
The significant differences in cefuroxime concentrations at
the times of surgical incision and wound closure were an
unexpected finding and indicate a change from the steady
state. The increased cefuroxime concentrations at closure
may have been due to intraoperative changes in drug clear-
ance. Cefazolin and cefuroxime are both eliminated renally
via glomerular filtration and tubular secretion. The renal
clearances of cefazolin and cefuroxime are 50 to 62 and 150
ml/min per 1.73 m2, respectively (8). General anesthetics
have been shown to cause intraoperative reductions in renal
blood flow and the glomerular filtration rate (5, 9, 14), and
cefuroxime, having a significantly higher renal clearance,
would be expected to be affected by these intraoperative
changes to a greater extent than cefazolin.
We assessed antimicrobial tissue penetration by mechan-
ically homogenizing wound muscle. As with any method of
determining antimicrobial tissue penetration, tissue homog-
enization has certain limitations. First, blood may contami-
nate the tissue sample, resulting in a falsely elevated con-
centration of drug in tissue (2). Second, the process of
homogenizing the tissue disturbs the anatomical relation-
ships within the tissue, resulting in a dilutional effect on
antibiotic in the extracellular space and underestimation of
the antibiotic concentration at the site of most bacterial
infections (13, 16). Previous experiences with the methods
employed in this study have found blood contamination of
muscle tissue to be negligible (7). Although tissue homoge-
nization may result in underestimation of the antibiotic
concentration in the extracellular space, both study drugs
should be affected equally by this procedure.
Although the present study found a good correlation
between free drug in serum and total drug in muscle for
cefazolin, there was no such correlation for cefuroxime.
Also, cefazolin and cefuroxime concentrations in muscle
were similar, despite significantly different free drug concen-
trations in serum. These findings indicate that the free drug
concentration in serum alone is not a consistent predictor of
the total concentration in tissue. Further studies are needed
to determine the clinical significance of this finding.
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